# A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

> **NCT00106509** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 520 (—)

## Conditions studied

- Clostridium Enterocolitis
- Pseudomembranous Colitis

## Interventions

- **DRUG:** tolevamer potassium-sodium (GT267-004)

## Key facts

- **NCT ID:** NCT00106509
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 520 (—)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106509, "A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00106509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*